The Smad family and its role in pancreatic cancer

Indian Journal of Cancer

Volumn 48, Issue 3, 2011, Pages 351-360

  Singh, P ^a   Wig, J D ^b   Srinivasan, R ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Government Medical College and Hospital   (India)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Pancreatic cancer; smad family; Smad4; Smad6; Smad7; transforming growth factor beta

Indexed keywords

ACTIVIN; BONE MORPHOGENETIC PROTEIN; SMAD ANCHOR FOR RECEPTOR ACTIVATION; SMAD PROTEIN; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; BINDING AFFINITY; CAENORHABDITIS ELEGANS; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CARCINOGENESIS; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; DISEASE COURSE; DNA BINDING; DROSOPHILA MELANOGASTER; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MISSENSE MUTATION; MOLECULAR INTERACTION; NUCLEAR EXPORT SIGNAL; NUCLEAR LOCALIZATION SIGNAL; PANCREAS CANCER; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UBIQUITINATION;

CELL DIFFERENTIATION; CELL PROLIFERATION; DNA-BINDING PROTEINS; HUMANS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 80054000870     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.84939     Document Type: Article

References (115)

1. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-beta receptor. Nature 1994;370:341-7. (Pubitemid 2110860)
2. Massagué J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-91.
3. Souchelnytskyi S, Tamaki K, Engström U, Wernstedt C, ten Dijke P, Heldin CH. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem 1997;272:28107-15. (Pubitemid 27473621)
4. de Caestecker MP, Yahata T, Wang D, Parks WT, Huang S, Hill CS, et al. The Smad4 activation domain is a proline-rich, p300-dependent transcriptional activation domain. J Biol Chem 2000;275:2115-22. (Pubitemid 30060840)
5. de Winter JP, Roelen BA, ten Dijke P, van der Burg B, van den Eijndenvan Raaij AJ. DPC4 (SMAD4) mediates transforming growth factorbeta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 1997;14:1891-9. (Pubitemid 27217802)
6. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, et al. The MAD-related protein Smad7 associates with the TGF-beta receptor and functions as an antagonist of TGF-beta signaling. Cell 1997;89:1165-73. (Pubitemid 127678749)
7. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997;389:622-6. (Pubitemid 27446182)
8. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 1995;139:1347-58.
9. Derynck R, Gelbart WM, Harland RM, Heldin CH, Kern SE, Massague J, et al. Nomenclature: Vertebrate mediators of TGF-beta family signals. Cell 1996;87:173.
10. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
11. Shi Y, Hata A, Massague J, Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997;388:87-93. (Pubitemid 27283894)
12. Massague J, Wotton D. Transcriptional control by the TGF-b/Smad signaling system. EMBO J 2000;19:1745-54. (Pubitemid 30204386)
13. Massague J, Chen YG. Controlling TGF signaling. Genes Dev 2000;14:627-44.
14. Feng XH, Derynck R. A kinase subdomain of transforming growth factor-b (TGF-b) type I receptor determines the TGF-b intracellular signaling activity. EMBO J 1997;16:3912-22.
15. Chen YG, Hata A, Lo RS, Wotton D, Shi Y, Pavletich N, et al. Determinants of specificity in TGF-beta signal transduction. Genes Dev 1998;12:2144-52. (Pubitemid 28348038)
16. Huse M, Chen YG, Massagué J, Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 1999;96:425-36. (Pubitemid 29077596)
17. Wu G, Chen YG, Ozdamar B, Gyuricza CA, Chong PA, Wrana JL, et al. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science 2000;287:92-7.
18. Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGFbeta signal transduction. J Cell Sci 2001;114:4359-69. (Pubitemid 34082857)
19. Cook T, Urrutia R. TIEG proteins join the Smads as TGF-betaregulated transcription factors that control pancreatic cell growth. Am J Physiol Gastrointest Liver Physiol 2000;278:G513-21. (Pubitemid 30213116)
20. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700. (Pubitemid 36724933)
21. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J 1998;17:4056-65. (Pubitemid 28333989)
22. Shi Y. Structural insights on Smad function in TGF-beta signaling. Bioessays 2001;23:223-32. (Pubitemid 32192141)
23. Chacko BM, Qin B, Correia JJ, Lam SS, de Caestecker MP, Lin K. The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization. Nat Struct Biol 2001;8:248-53. (Pubitemid 32180052)
24. Correia JJ, Chacko BM, Lam SS, Lin K. Sedimentation studies reveal a direct role of phosphorylation in Smad3:Smad4 homo- and heterotrimerization. Biochemistry 2001;40:1473-82. (Pubitemid 32142909)
25. Wu RY, Zhang Y, Feng XH, Derynck R. Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4. Mol Cell Biol 1997;17:2521-8. (Pubitemid 27175133)
26. Fink SP, Mikkola D, Willson JK, Markowitz S. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene 2003;22:1317-23. (Pubitemid 36384592)
27. Masuyama N, Hanafusa H, Kusakabe M, Shibuya H, Nishida E. Identification of two Smad4 proteins in Xenopus. Their common and distinct properties. J Biol Chem 1999;274:12163-70.
28. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-6. (Pubitemid 26230501)
29. Mamot C, Mild G, Reuter J, Laffer U, Metzger U, Terracciano L, et al. Infrequent mutation of the tumour-suppressor gene Smad4 in earlystage colorectal cancer. Br J Cancer 2003;88:420-3. (Pubitemid 36308154)
30. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-71. (Pubitemid 28013118)
31. Souchelnytskyi S, Nakayama T, Nakao A, Morén A, Heldin CH, Christian JL, et al. Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenetic protein receptors and transforming growth factor-beta receptors. J Biol Chem 1998;273:25364-70. (Pubitemid 28443303)
32. Itoh S, Landstrom M, Hermansson A, Itoh F, Heldin CH, Heldin NE, et al. Transforming growth factor beta1 induces nuclear export of inhibitory Smad7. J Biol Chem 1998;273:29195-201. (Pubitemid 28507620)
33. Hata A, Lagna G, Massague J, Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 1998;12:186-97. (Pubitemid 28060449)
34. Ishisaki A, Yamato K, Hashimoto S, Nakao A, Tamaki K, Nonaka K, et al. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and Activin-mediated growth arrest and apoptosis in B cells. J Biol Chem 1999;274:13637-42.
35. Nakao A, Afrakhte M, Morén A, Nakayama T, Christian JL, Heuchel R, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997;389:631-5. (Pubitemid 27446184)
36. Ulloa L, Doody J, Massagué J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999;397:710-3.
37. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev 2000;14:187-97. (Pubitemid 30070984)
38. Hata A, Lo RS, Wotton D, Lagna G, Massagué J. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature 1997;388:82-7. (Pubitemid 27283893)
39. Dong C, Li Z, Alvarez R, Feng XH, Goldschmidt-Clermont PJ. Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 2000;5:27-34. (Pubitemid 30105433)
40. Sasaki A, Masuda Y, Ohta Y, Ikeda K, Watanabe K. Filamin associates with Smads and regulates transforming growth factor-beta signaling. J Biol Chem 2001;276:17871-7.
41. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 2003;5:410-21. (Pubitemid 36592263)
42. Lin HK, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGFbeta signalling. Nature 2004;431:205-11. (Pubitemid 39243475)
43. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 1998;95:779-91. (Pubitemid 29014458)
44. Furuhashi M, Yagi K, Yamamoto H, Furukawa Y, Shimada S, Nakamura Y, et al. Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway. Mol Cell Biol 2001;21:5132-41. (Pubitemid 32656409)
45. Hocevar BA, Smine A, Xu XX, Howe PH. The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J 2001;20:2789-801. (Pubitemid 32938562)
46. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massague J, et al. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 1999;401:480-5. (Pubitemid 29470206)
47. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999;400:687-93.
48. Lin X, Liang M, Feng XH. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 2000;275:36818-22. (Pubitemid 32002092)
49. Itoh F, Asao H. Sugamura K, Heldin CH, ten Dijke P, Itoh S. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J 2001;20:4132-42. (Pubitemid 32751829)
50. Liu X, Sun Y, Weinberg RA, Lodish HF. Ski/Sno and TGF-beta signaling. Cytokine Growth Factor Rev 2001;12:1-8.
51. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signaling pathways converge on the TGF-beta family mediator Smad1. Nature 1997;389:618-22. (Pubitemid 27446181)
52. Wicks SJ, Lui S, Abdel-Wahab N, Mason RM, Chantry A. Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II. Mol Cell Biol 2000;20:8103-11.
53. Yakymovych I, Ten Dijke P, Heldin CH, Souchelnytskyi S. Regulation of Smad signaling by protein kinase C. FASEB J 2001;15:553-5.
54. Fukuchi M, Imamura T, Chiba T, Ebisawa T, Kawabata M, Tanaka K, et al. Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. Mol Biol Cell 2001;12:1431-43. (Pubitemid 33044422)
55. Izzi L, Attisano L. Regulation of the TGF-beta signalling pathway by ubiquitin-mediated degradation. Oncogene 2004;23:2071-8. (Pubitemid 38496736)
56. Watanabe M, Masuyama N, Fukuda M, Nishida E. Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal. EMBO Rep 2000;1:176-82.
57. Howell M, Itoh F, Pierreux CE, Valgeirsdottir S, Itoh S, ten Dijke P, et al. Xenopus Smad4beta is the co-Smad component of developmentally regulated transcription factor complexes responsible for induction of early mesodermal genes. Dev Biol 1999;214:354-69. (Pubitemid 29483098)
58. Itoh S, Landstrom M, Hermansson A, Itoh F, Heldin CH, Heldin NE, et al. Transforming growth factor beta1 induces nuclear export of inhibitory Smad7. J Biol Chem 1998;273:29195-201. (Pubitemid 28507620)
59. Kurisaki A, Kose S, Yoneda Y, Heldin CH, Moustakas A. Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beta1 and Ran-dependent manner. Mol Biol Cell 2001;12:1079-91. (Pubitemid 33052000)
60. Pierreux CE, Nicolás FJ, Hill CS. Transforming growth factor betaindependent shuttling of Smad4 between the cytoplasm and nucleus. Mol Cell Biol 2000;20:9041-54. (Pubitemid 32245933)
61. Xiao Z, Liu X, Henis YI, Lodish HF. A distinct nuclear localization signal in the N terminus of Smad 3 determines its ligand induced nuclear translocation. Proc Natl Acad Sci USA 2000;97:7853-8. (Pubitemid 30460737)
62. Xu L, Kang Y, Cöl S, Massagué J. Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGF-beta signaling complexes in the cytoplasm and nucleus. Mol Cell 2002;10:271-82. (Pubitemid 35007342)
63. Xu L, Alarcón C, Cöl S, Massagué J. Distinct domain utilization by Smad3 and Smad4 for nucleoporin interaction and nuclear import. J Biol Chem 2003;278:42569-77. (Pubitemid 37310530)
64. Chen HB, Rud JG, Lin K, Xu L. Nuclear Targeting of Transforming Growth Factor-b-activated Smad Complexes. J Biol Chem 2005;280:21329-36. (Pubitemid 40805695)
65. Inman GJ, Nicolas FJ, Hill CS. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol Cell 2002;10:283-94. (Pubitemid 35007343)
66. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998;1:611-7. (Pubitemid 128374697)
67. Denissova NG, Pouponnot C, Long J, He D, Liu F. Transforming growth factor beta -inducible independent binding of SMAD to the Smad7 promoter. Proc Natl Acad Sci USA 2000;97:6397-402. (Pubitemid 30412725)
68. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091-100. (Pubitemid 28254381)
69. Shi Y, Wang YF, Jayaraman L, Yang H, Massagué J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA binding in TGF-beta signaling. Cell 1998;94:585-94. (Pubitemid 28427577)
70. Labbé E, Silvestri C, Hoodless PA, Wrana JL, Attisano L. Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol Cell 1998;2:109-20. (Pubitemid 128378972)
71. Dennler S, Huet S, Gauthier JM. A short amino-acid sequence in MH1 domain is responsible for functional differences between Smad2 and Smad3. Oncogene 1999;18:1643-8. (Pubitemid 29108066)
72. Yagi K, Goto D, Hamamoto T, Takenoshita S, Kato M, Miyazono K. Alternatively-spliced variant of Smad2 lacking exon 3: Comparison with wild-type Smad2 and Smad3. J Biol Chem 1999;274:703-9.
73. Friess H, Yamanaka Y, Büchler M, Ebert M, Beger HG, Gold LI, et al. Enhanced expression of transforming growth factor-beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-56. (Pubitemid 24002804)
74. Lu Z, Friess H, Graber HU, Guo X, Schilling M, Zimmermann A, et al. Presence of two signaling TGF- beta receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 1997;42:2054-63. (Pubitemid 27501990)
75. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
76. Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Büchler MW, et al. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 1999;116:1202-16. (Pubitemid 29203031)
77. Levy L, Hill CS. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 2005;25:8108-25. (Pubitemid 41263004)
78. Chow JY, Quach KT, Cabrera BL, Cabral JA, Beck SE, Carethers JM. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 2007;28:2321-7. (Pubitemid 350111590)
79. Ottaviano AJ, Sun L, Ananthanarayanan V, Munshi HG. Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer Res 2006;66:7032-40. (Pubitemid 44197679)
80. Chow JY, Ban M, Wu HL, Nguyen F, Huang M, Chung H, et al. TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2010;298:G275-82.
81. Zhao S, Venkatasubbarao K, Lazor JW, Sperry J, Jin C, Cao L, et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 2008;68:4221-8.
82. Chow JY, Dong H, Quach KT, Van Nguyen PN, Chen K, Carethers JM. TGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha activation in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2008;294:G899-905. (Pubitemid 351520064)
83. Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S, et al. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res 2004;64:5200-11. (Pubitemid 39006539)
84. Gaspar NJ, Li L, Kapoun AM, Medicherla S, Reddy M, Li G, et al. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol Pharmacol 2007;72:152-61. (Pubitemid 46998534)
85. Gadir N, Jackson DN, Lee E, Foster DA. Defective TGF-beta signaling sensitizes human cancer cells to rapamycin. Oncogene 2008;27:1055-62. (Pubitemid 351253184)
86. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
87. Kim SJ, Im YH, Markowitz SD, Bang YJ. Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 2000;11:159-68. (Pubitemid 30169736)
88. Adrian K, Strouch MJ, Zeng Q, Barron MR, Cheon EC, Honasoge A, et al. Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer. Cancer Res 2009;69:9169-74.
89. Grady WM, Rajput A, Myeroff L, Liu DF, Kwon KH, Willis J, et al. Mutation of the Type II Transforming Growth Factor-β Receptor Is Coincident with the Transformation of Human Colon Adenomas to Malignant Carcinomas. Cancer Res 1998;58:3101-4. (Pubitemid 28335093)
90. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF- β signaling. Proc Natl Acad Sci USA 2007;104:3460-5. (Pubitemid 46364181)
91. van Heek T, Rader AE, Offerhaus GJ, McCarthy DM, Goggins M, Hruban RH, et al. K-ras, p53, and DPC4 (MAD4) alterations in fineneedle aspirates of the pancreas: A molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 2002;117:755-65. (Pubitemid 34457011)
92. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-30. (Pubitemid 26170688)
93. Hruban RH, Wilentz RE, Goggins M, Offerhaus GJ, Yeo CJ, Kern SE. Pathology of incipient pancreatic cancer. Ann Oncol 1999;10:9-11.
94. Hruban RH, Offerhaus GJ, Kern SE, Goggins M, Wilentz RE, Yeo CJ. Tumor-suppressor genes in pancreatic cancer. J Hepatobiliary Pancreat Surg 1998;5:383-91. (Pubitemid 128662609)
95. Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH, Kern SE. Missense mutations of MADH4: Characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res 2004;10:1597-604. (Pubitemid 38435548)
96. Maurice D, Pierreux CE, Howell M, Wilentz RE, Owen MJ, Hill CS. Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability. J Biol Chem 2001;276:43175-81.
97. Xu J, Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor-beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 2000;97:4820-5. (Pubitemid 30238641)
98. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-72. (Pubitemid 30637716)
99. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27:1806-13.
100. Xu X, Ehdaie B, Ohara N, Yoshino T, Deng CX. Synergistic action of Smad4 and Pten in supressing pancreatic ductal adenocarcinoma formation in mice. Oncogene 2010;29:674-86.
101. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006;20:3130-46. (Pubitemid 44790628)
102. Hua Z, Zhang YC, Hu XM, Jia ZG. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J Gastroenterol 2003;9:2764-7. (Pubitemid 38054456)
103. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009; 15:4674-9.
104. Ali S, Cohen C, Little JV, Sequeira, JH, Mosunjac MB, Siddiqui MT. The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors. Diagn Cytopathol 2007;35:644-8. (Pubitemid 47530421)
105. Yasutome M, Gunn J, Korc M. Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis. Clin Exp Metastasis 2005;22:461-73. (Pubitemid 41750698)
106. Shen W, Tao GQ, Li DC, Zhu XG, Bai X, Cai B. Inhibition of pancreatic carcinoma cell growth in vitro by DPC4 gene transfection. World J Gastroenterol 2008;14:6254-60.
107. Wang H, Han H, Von Hoff DD. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res 2006;66:9722-30. (Pubitemid 44623673)
108. Wang H, Stephens B, Von Hoff DD, Han H. Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells. Pancreas 2009;38:551-7.
109. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999;18:5363-72. (Pubitemid 29469224)
110. Guo J, Kleeff J, Zhao Y, Li J, Giese T, Esposito I, et al. Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. Int J Mol Med 2006;17:761-7.
111. Arnold NB, Ketterer K, Kleef J, Friess H, Buchler MW, Korc M. Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. Cancer Res 2004;64:3599-606. (Pubitemid 38657938)
112. Wang P, Fan J, Chen Z, Meng ZQ, Luo JM, Lin JH, et al. Low-level expression of Smad7 correlates with lymph node metastasis and poor prognosis in patients with pancreatic cancer. Ann Surg Oncol 2009;16:826-35.
113. Ellenrieder V, Buck A, Harth A, Jungert K, Buchholz M, Adler G, et al. KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-MAPK in pancreatic cancer cells. Gastroenterology 2004;127:607-20. (Pubitemid 39091908)
114. Arnold NB, Korc M. Smad7 abrogates transforming growth factorbeta1- mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein. J Biol Chem 2005;280:21858-66. (Pubitemid 40827837)
115. Jonson T, Gorunova L, Dawiskiba S, Andren-Sandberg A, Stenman G, ten Dijke P, et al. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer. Genes Chromosomes Cancer 1999;24:62-71. (Pubitemid 28544464)